A biotechnology startup has announced plans to develop a groundbreaking weight loss drug designed specifically to address the unique metabolic needs of older adults. BioAge, a California-based company, is collaborating with pharmaceutical giant Eli Lilly to create tailored solutions for weight management in aging populations.
BioAge, known for its innovative approach to treating metabolic diseases, has filed for an initial public offering (IPO) to fuel its efforts in tackling obesity. Their lead drug candidate, Azelaprag, mimics apelin—a peptide that naturally declines with age and is usually released during physical activity. Early clinical trials have shown that Azelaprag, when combined with existing injectable weight loss treatments, can enhance fat reduction while preventing muscle loss, a common issue with many weight loss therapies.
In addition to Azelaprag, BioAge is conducting a phase 2 trial involving Tizerpertide, the key ingredient in Eli Lilly’s weight loss drug Zepbound. The company is also exploring how Azelaprag could work alongside semaglutide, the active compound in Novo Nordisk’s popular treatments Wegovy and Ozempic.
The announcement comes at a time when demand for weight loss drugs is at an all-time high, with major players like Pfizer and Roche also stepping into the obesity treatment market. The focus on developing effective, long-term weight management solutions for seniors marks a pivotal shift in obesity care, as older adults often face greater challenges in maintaining a healthy weight due to age-related metabolic changes.
As competition heats up, the future of obesity treatment appears poised for rapid advancement, with new options potentially transforming weight management for aging populations.
